ARDELYX INC
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
ARDX$2.93+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Throughout this 2024 Form 10-K, we have used terms which are defined below:
| 340B Program | Public Health Service’s 340B Drug Pricing Program | HCR Agreement | Royalty and Sales Milestone Interest Acquisition Agreement |
|---|---|---|---|
| AAKP | American Association of Kidney Patients | HHS | Department of Health and Human Services |
| ACA | Affordable Care Act | HIPAA | Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder |
| AI Technologies | Artificial intelligence, machine learning and certain automated decision-making technologies | HRSA | Health Resources and Services Administration |
| AMP | average manufacturer price | IBS-C | irritable bowel syndrome with constipation |
| ANDA | abbreviated New Drug Application | IND | Investigational New Drug |
| API | active pharmaceutical ingredient | IRA | Inflation Reduction Act of 2022 |
| AstraZeneca | AstraZeneca AB | IRB | institutional review board |
| ASU | Accounting Standards Update | Jefferies | Jefferies, LLC |
| CCPA | California Consumer Privacy Act, as amended by the California Privacy Rights Act | Kyowa Kirin | Kyowa Kirin Co., Ltd. |
| cGMP | current Good Manufacturing Practice | Knight | Knight Therapeutics, Inc. |
| CKD | chronic kidney disease | MDRP | Medicaid Drug Rebate Program |
| CME | Chicago Mercantile Exchange | METiS | METiS Therapeutics, Inc. |
| CMO | contract manufacturing organization | MHLW | Ministry of Health, Labour and Welfare |
| CMS | Centers for Medicare & Medicaid Services | MIPPA | Medicare Improvements for Patients andProviders Act |
| CRO | contract research organization | OLC | Oxylanthanum Carbonate |
| Customers | collectively, major wholesalers, specialty pharmacies and GPOs (IBSRELA) and specialty wholesaler (XPHOZAH) | NCE | new chemical entity |
| DPF | EU-US Data Privacy Framework | NDA | New Drug Application |
| EEA | European Economic Area | NH3 | sodium hydrogen exchange 3 |
| ESPP | Employee Stock Purchase Plan | NMPA | National Medical Products Administration |
| ESRD | End-Stage Renal Disease | NOL | net operating loss |
| ESRD PPS | End-Stage Renal Disease Prospective Payment System | NMQF | National Minority Quality Forum |
| EU Patent Package | European Patent Package | Non-FAMP | Non-Federal Average Manufacturer Price |
| FASB | Financial Accounting Standards Board | R&D | research and development |
| FDA | Food and Drug Administration | REMS | Risk Evaluation and Mitigation Strategy |
| FFDCA | Federal Food, Drug, and Cosmetic Act | RSU | restricted stock units |
| Fosun Pharma | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | SLR | SLR Investment Corp. |
| FSS | Federal Supply Schedule | SEC | Securities and Exchange Commission |
| FTC | Federal Trade Commission | SOFR | Secured Overnight Financing Rate |
| GCP | Good Clinical Practice | TDAPA | Transitional Drug Add-on Payment Adjustment |
| GDPR | European Union General Data Protection Regulation | UPC | European Unified Patent Court |
| GLP | Good Laboratory Practice | U.S. | United States |
| GPO | group purchasing organization | USPTO | U.S. Patent and Trademark Office |
| GTN | gross-to-net | VA | Department of Veterans Affairs |
| HCR | HealthCare Royalty Partners IV, L.P. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.